Harwood Feffer LLP Announces Investigation of Tetraphase Pharmaceuticals Inc.

Feb 04, 2016, 17:03 ET from Harwood Feffer LLP

NEW YORK, Feb. 4, 2016 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Tetraphase Pharmaceuticals Inc. ("Tetraphase" or the "Company") (NASDAQ: TTPH), concerning whether the board has breached its fiduciary duties to shareholders.

On September 8, 2015, the Company announced the results of an important part of the IGNITE2 phase 3 clinical trial of Eravacycline.  The disclosure stated that Eravacycline, administered as an intravenous (IV) to oral transition therapy for the treatment of complicated urinary tract infections and failed to achieve its primary endpoint of statistical non-inferiority compared to Levofloxacin under the guidelines established by both the FDA and EMA.

On this news, Company stock dropped from $44.78 to $8.36 per share in two days.

Our investigation concerns whether the Company board of directors has breached its fiduciary duties to shareholders, grossly mismanaged the Company, and/or committed abuses of control in connection with the foregoing.

If you own Tetraphase shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:

Robert I. Harwood, Esq. Benjamin I. Sachs-Michaels, Esq. Harwood Feffer LLP 488 Madison Avenue New York, New York 10022 Phone Numbers: (877) 935-7400 (212)935-7400 Email:  bsachsmichaels@hfesq.com Website:   http://www.hfesq.com  Follow us on Twitter: @HarwoodFeffer

Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for more information about the firm. 

Attorney Advertising. The law firm responsible for this advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Logo - http://photos.prnewswire.com/prnh/20120215/MM54604LOGO


SOURCE Harwood Feffer LLP